title: [Comparison of two conditioning regimens in treatment of leukemia by allogeneic hematopoietic stem cell transplantation].
abstract: OBJECTIVE
  The conditioning regimens are the critical factors in the allogeneic hematopoietic stem cell transplantation. This study was conducted to compare the effectiveness and side-effects of two conditioning regimens in allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  
  
  METHODS
  Twenty-one cases received busulfan(BU) 16 mg/kg plus cyclophosphamide(CY) 120 mg/kg,the other 23 cases received total body irradiation(TBI) 7.5-8.5 Gy plus CY 120 mg/kg regimen.
  
  
  RESULTS
  The 3-year disease-free survivals (DFS) were 61.5% in BU/CY group and 64.7% in TBI/CY group, respectively (P >0.05). The relapse rates were 23.8% and 26%, respectively, without significant difference (P >0.05). The incidence of liver damage in the BU/CY group was higher (80.9%) than that in the TBI/CY group (54.3%) (P< 0.05), while no case developed hepatic veno-occlusive disease. Stomatitis and gastrointestinal toxicity were significantly lower in the BU/CY group (33.3% and 42.9%) compared with TBI/CY group (78.2% and 78.2%), respectively (P< 0.05). Bladder toxicity (23.8% and 26%) and pulmonary toxicity(14.3% and 13%) were similar in the two groups(P >0.05), while one patient in TBI/CY group developed grade IV pulmonary toxicity, which is lethal. No case was found to have cardiac, renal, or central nervous system grade I toxicity.
  
  
  CONCLUSIONS
  The two groups have equal effectiveness, BU/CY regimen is relatively easy to administer and well tolerated with low extramedullary toxicity.
authors.affiliation: Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, PR China. zhangguocai1946@21cn.com
authors.forename: Guo-Cai
authors.initials: GC
authors.lastname: Zhang
authors.forename: Dong
authors.initials: D
authors.lastname: Zheng
authors.forename: Xun-Xing
authors.initials: XX
authors.lastname: Guan
authors.forename: Shao-Kai
authors.initials: SK
authors.lastname: Luo
authors.forename: Juan
authors.initials: J
authors.lastname: Li
authors.forename: Ai-Hua
authors.initials: AH
authors.lastname: Peng
authors.forename: Xiu-Zhen
authors.initials: XZ
authors.lastname: Tong
authors.forename: Feng-Zhen
authors.initials: FZ
authors.lastname: Lai
authors.forename: En-Xun
authors.initials: EX
authors.lastname: Tan
authors.forename: Wen-De
authors.initials: WD
authors.lastname: Hong
mesh_terms: D000293:Adolescent; D000328:Adult; D002066:Busulfan / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007938:Leukemia / Q000401:mortality / Q000628:therapy*; D008297:Male; D012008:Recurrence; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D014916:Whole-Body Irradiation
chemical_list: D003520:Cyclophosphamide; D002066:Busulfan